Kidney Cancer | Tumor

Friday Frontline: Man With Late-Stage Cancer Gets Matching Tattoos with Strangers, 78-Year-Old Cancer Survivor Earns Black Belt

June 18th 2021, 3:00pm


From a man with late-stage cancer who has matching tattoos with over 400 strangers to a 78-year-old cancer survivor getting his black belt in Taekwondo, here’s what’s happening in the cancer landscape this week.

Keytruda-Inlyta Combo Continues to Improve Survival in Kidney Cancer

June 10th 2021, 6:00pm


Use of the combination of Keytruda and Inlyta is associated with long-term survival benefits in patients with kidney cancer.

Fotivda Nearly Doubles Duration of Response Compared With Nexavar in Metastatic Kidney Cancer

June 6th 2021, 6:00pm


In patients with metastatic renal cell carcinoma who have failed on two prior therapies, Fotivda, compared with Nexavar, contributed to a duration of response of 20.3 months versus 9 months.

Keytruda After Surgery Significantly Improves Survival in Patients with Kidney Cancer

June 4th 2021, 6:30pm


Treatment with Keytruda following surgery was associated with a significant reduction in the risk of disease recurrence or death compared with placebo in patients with clear cell renal cell carcinoma.

FDA Grants Keytruda-Lenvima Combo Priority Review for Treatment of Advanced Kidney Cancer and Endometrial Cancer

May 6th 2021, 1:52pm


The priority review will focus on the combination of Keytruda and Lenvima for the first-line treatment of advanced renal cell carcinoma, as well as the treatment of certain patients with endometrial carcinoma.

Higher BMI May Be Associated With Improved Overall Survival in Patients with Metastatic Kidney Cancer

April 22nd 2021, 6:00pm


Recent data found an association between higher BMI and better overall survival among patients with metastatic renal cell carcinoma who were treated with immune checkpoint inhibitors.

Active Surveillance Occurs Frequently Versus Systemic Therapy for Metastatic Renal Cell Carcinoma

April 20th 2021, 9:00pm


Certain patients with metastatic renal cell carcinoma may benefit with active surveillance compared with systemic therapy for their management and may also lead to an improved quality of life.

Inlyta Shows Promise for Metastatic Clear Cell Renal Cell Carcinoma

April 19th 2021, 1:00pm


Inlyta alone demonstrates longer progression-free survival compared to Inlyta in combination with carotuximab.

NCCN Recommends Lenvima Plus Keytruda for First-Line Renal Cell Carcinoma: What Patients Should Know

April 9th 2021, 1:00pm


CURE spoke with Dr. Eric Jonasch about the National Comprehensive Cancer Network’s Category 1 recommendation for the combination use of Lenvima plus Keytruda for the treatment of front-line renal cell carcinoma. In particular, how it can impact a patient’s treatment journey.

FDA’s Fotivda Approval Provides Certain Patients With Kidney Cancer ‘Another Future Treatment Option’

March 24th 2021, 6:00pm


The biggest reason the FDA’s recent approval of Fotivda is important for adults with relapsed or refractory advanced renal cell carcinoma who have received two or more prior systemic therapies, according to an expert from the Vanderbilt-Ingram Cancer Center, is that it offers them a very tolerable treatment option that may preserve quality of life.